Synergistic effects of systemic trefoil factor family 1 (TFF1) peptide and epidermal growth factor in a rat model of colitis

This publication has 29 references indexed in Scilit:

• Selective abrogation of the proinvasive activity of the trefoil peptides pS2 and spasmolytic polypeptide by disruption of the EGF receptor signaling pathways in kidney and colonic cancer cells
  Oncogene, 2003
• Animal models of inflammatory bowel disease
  The Esophagus, 2002
• Potency and stability of C terminal truncated human epidermal growth factor
  Gut, 2000
• Trefoil peptide TFF2 (spasmolytic polypeptide) potently accelerates healing and reduces inflammation in a rat model of colitis
  Gut, 1999
• Gastric Mucosa Abnormalities and Tumorigenesis in Mice Lacking the pS2 Trefoil Protein
  Science, 1996
• The epidermal growth factor receptor (EGF-R) is present on the basolateral, but not the apical, surface of enterocytes in the human gastrointestinal tract.
  Gut, 1996
• Peptides and gastrointestinal mucosal integrity.
  Gut, 1995
• Epidermal growth factor in necrotising enteritis
  The Lancet, 1991
• Enhancement of Wound Healing by Topical Treatment with Epidermal Growth Factor
  New England Journal of Medicine, 1989
• Immunohistochemical localisation of urogastrone to human duodenal and submandibular glands.
  Gut, 1978